A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Clinical Trial ID NCT01774851

Rank	Title	Journal	Year	PubWeight™‹?›
1	Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.	Nat Rev Drug Discov	2014	2.20
2	Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.	BioDrugs	2015	0.87
3	Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).	Mol Clin Oncol	2013	0.86
4	Targeted therapies in gastric cancer and future perspectives.	World J Gastroenterol	2016	0.86
5	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.	Am J Transl Res	2015	0.83
6	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.	Hum Vaccin Immunother	2015	0.81
7	Novel targets in the treatment of advanced gastric cancer: a perspective review.	Ther Adv Med Oncol	2016	0.79
8	Co-opting biology to deliver drugs.	Biotechnol Bioeng	2014	0.79
9	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.	MAbs	2016	0.77